DK1789026T3 - Fremgangsmåde til systematisk biokorrektion af en organisme - Google Patents

Fremgangsmåde til systematisk biokorrektion af en organisme

Info

Publication number
DK1789026T3
DK1789026T3 DK05766946.7T DK05766946T DK1789026T3 DK 1789026 T3 DK1789026 T3 DK 1789026T3 DK 05766946 T DK05766946 T DK 05766946T DK 1789026 T3 DK1789026 T3 DK 1789026T3
Authority
DK
Denmark
Prior art keywords
respiratory quotient
organism
cell
adjusting
treatment
Prior art date
Application number
DK05766946.7T
Other languages
English (en)
Inventor
Alexander Viktorowitsch Kuzin
Joerg Schulz
Peter Bendzko
Oleg Wladimirowitsch Drogobych
Original Assignee
Inst Molekular Und
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Molekular Und filed Critical Inst Molekular Und
Application granted granted Critical
Publication of DK1789026T3 publication Critical patent/DK1789026T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
DK05766946.7T 2004-07-16 2005-07-08 Fremgangsmåde til systematisk biokorrektion af en organisme DK1789026T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004034640A DE102004034640A1 (de) 2004-07-16 2004-07-16 Verfahren zur systemischen Biokorrektur eines Organismus
PCT/DE2005/001224 WO2006007818A2 (de) 2004-07-16 2005-07-08 Verfahren zur systemischen biokorrektur eines organismus

Publications (1)

Publication Number Publication Date
DK1789026T3 true DK1789026T3 (da) 2011-05-02

Family

ID=35668413

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05766946.7T DK1789026T3 (da) 2004-07-16 2005-07-08 Fremgangsmåde til systematisk biokorrektion af en organisme

Country Status (5)

Country Link
EP (1) EP1789026B1 (da)
AT (1) ATE493975T1 (da)
DE (2) DE102004034640A1 (da)
DK (1) DK1789026T3 (da)
WO (1) WO2006007818A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264520A1 (en) 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
DE102011050038A1 (de) 2011-05-02 2012-11-08 Rapido-Tech Gmbh Reinigungsvorrichtung für Backplatten einer Backautomatenanlage
ES2539187T3 (es) 2012-03-30 2015-06-26 Nl Nanomed Limited Procedimiento para el control de un aparato de entrenamiento

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524275D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
SE505391C2 (sv) 1995-05-30 1997-08-18 Cortendo Ab Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
WO1999058120A1 (en) 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
AT407950B (de) * 1999-05-25 2001-07-25 Hoffmann La Roche Verfahren und vorrichtung zur ermittlung eines von respiratorischen messdaten abhängigen indikators
AU5821800A (en) * 1999-06-29 2001-01-31 Heiner Stegmann Method for adjusting or controlling the diet and/or a person's consumption
RU2185826C1 (ru) 2001-02-02 2002-07-27 Балаболкин Михаил Иванович Средство для коррекции метаболического синдрома и способ лечения сосудистых осложнений, вызванных нарушением углеводного обмена

Also Published As

Publication number Publication date
ATE493975T1 (de) 2011-01-15
EP1789026A2 (de) 2007-05-30
DE102004034640A1 (de) 2006-02-16
WO2006007818A2 (de) 2006-01-26
WO2006007818A3 (de) 2006-05-18
DE502005010810D1 (de) 2011-02-17
EP1789026B1 (de) 2011-01-05

Similar Documents

Publication Publication Date Title
EA201071379A1 (ru) Получение бутандиола с помощью анаэробной микробной ферментации
ATE532871T1 (de) Transformierte pflanzen mit verbesserter biosynthese von prenylquinonen
MX2009010894A (es) Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.
WO2009074792A3 (en) Substituted benzoquinones and hydroquinones in the treatment of periodontal diseases
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
EP2429944A4 (en) SYSTEM FOR PRODUCING HIGH-CONCENTRATED NO2 AND METHOD FOR GENERATING HIGH-CONCENTRATED NO2 USING THE GENERATION SYSTEM
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
DK1789026T3 (da) Fremgangsmåde til systematisk biokorrektion af en organisme
Zhou et al. Hydrogen-rich water to enhance exercise performance: a review of effects and mechanisms
RU2007113515A (ru) Способ психологической коррекции избыточной массы тела
BRPI0418799A (pt) método para produzir ácido succìnico de hidrolisados de tipo industrial, e, mutante bacteriano
Upadhyay et al. Photobiomodulation strengthens muscles via its dual functions in gut microbiota
Daraei et al. The effect of physical activity on vitamin D levels and improving sleep quality in women
BRPI0811649B8 (pt) método para produzir fator de von willebrand maduro a partir de pró-peptídeo de fator de von willebrand
NO20090292L (no) Fenyleddiksyrederivater
ATE395414T1 (de) Glukose dehydrogenase und ihre herstellung
Ruiz et al. Reduction Of GM-CSF Release In Human Airway Smooth Muscle Cells By Carbon Monoxide, Hypoxia, And Anoxia
Dayringer Trends in pastoral counseling for the 21st century
Kondratiev et al. Characteristics of adjustment of a developing personality in the situation of emergence of a student group
Katz et al. Music Technology
Danchev Abelian groups with a nice basis
RU2009118648A (ru) Способ осуществления кардиоплегии
Kontodimopoulos et al. A comparison of the efficiency of public and private dialysis units
문소영 Principles of piano-playing music therapy